53704 Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices 

Name of Committee: Center for Inherited 

Disease Research Access Committee. 

Date: September 14, 2010. 

Time: 11:30 a.m. to 12:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5635 

Fishers Lane, Suite 4069, Bethesda, MD 

20892, (Telephone Conference Call) 

Contact Person: Ken D. Nakamura, PhD, 

Scientific Review Officer, Scientific Review 

Branch, National Human Genome Research 

Institute, National Institutes of Health, 5635 

Fishers Lane, Suite 4076, MSC 9306, 

Rockville, MD 20852, 301–402–0838. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: August 26, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–21819 Filed 8–31–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Use of Pentosan Polysulfate 

To Treat Certain Conditions of the 

Prostate 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the invention 

embodied in U.S. Patent Application 

No. 10/209,331, filed July 30, 2002, 

which was issued as U.S. Patent 

6,828,309 on December 07, 2004, 

entitled, ‘‘USE OF PENTOSAN 

POLYSULFATE TO TREAT CERTAIN 

CONDITIONS OF THE PROSTATE,’’ 

developed by Dr. Gary Striker (formerly 

of NIDDK) [HHS Ref. No. E–104–1997/ 

0–US–03], to Swati Spentose Private 

Limited, having a place of business in 

Mumbai, India. The patent rights in this 

invention have been assigned to the 

United States of America. 

The contemplated exclusive license 

territory may be worldwide, and the 

field of use may be limited to ‘‘the use 

of pentosan polysulfate for the treatment 

or prevention of benign prostatic 

hyperplasia.’’ 

DATES: Only written comments and/or 

application for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

October 1, 2010 will be considered. 

ADDRESSES: Requests for copies of the 

patents, inquiries, comments, and other 

materials relating to the contemplated 

license should be directed to: 

Suryanarayana Vepa, PhD, J.D., 

Licensing and Patenting Manager, Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: 301–435–5020; 

Facsimile: 301–402–0220; E-mail: 

vepas@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: This 

technology is a method for treating 

Benign Prostatic Hyperplasia (BHP) 

using the oral medication pentosan 

polysulfate (PPS). PPS is a well known, 

semi-synthetic polysaccharide extracted 

from beech wood cellulose that is FDA 

approved for the treatment of interstitial 

fibrosis. The current technology builds 

on the surprising discovery that PPS can 

cause regression of scarring and lesions 

in prostatic tissue. PPS reduces or 

eliminates both smooth muscle cell 

proliferation and extracellular matrix 

deposition, and so reduces the size of 

the prostate gland and decreases 

associated obstructive symptoms. 

The prospective exclusive license will 

be royalty-bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless, 

within 30 days from the date of this 

published Notice, the NIH receives 

written evidence and argument that 

establishes that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR 404.7. 

Applications for a license in the 

prospective field of use filed in response 

to this notice will be treated as 

objections to the grant of the 

contemplated exclusive license. 

Comments and objections submitted in 

response to this notice will not be made 

available for public inspection, and, to 

the extent permitted by law, will not be 

released under the Freedom of 

Information Act, 5 U.S.C. 552. 

Dated: August 25, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

& Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–21818 Filed 8–31–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0427] 

Public Workshop on Medical Devices 

and Nanotechnology: Manufacturing, 

Characterization, and Biocompatibility 

Considerations; Correction 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; correction. 

SUMMARY: The Food and Drug 

Administration (FDA) is correcting a 

notice that appeared in the Federal 

Register of August 23, 2010 (75 FR 

51829). The notice announced the 

public workshop entitled ‘‘Medical 

Devices & Nanotechnology: 

Manufacturing, Characterization, and 

Biocompatibility Considerations.’’ The 

notice was published with an incorrect 

registration Web site. This document 

corrects that Web site. 

FOR FURTHER INFORMATION CONTACT: Paul 

Gadiock, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 66, rm. 4432, Silver Spring, 

MD 20993–0002, 301–796–5736. 

SUPPLEMENTARY INFORMATION: In FR Doc. 

2010–20837, appearing on page 51829 

in the Federal Register of Monday, 

August 23, 2010, the following 

correction is made: 

1. On page 51829, in the second 

column, in the Registration and 

Requests for Oral Presentations section, 

in the first full paragraph, beginning in 

the third line, ‘‘http://www.fda.gov/ 

MedicalDevices/NewsEvents/ 

WorskshopsConferences/default.htm’’ is 

corrected to read ‘‘http://www.fda.gov/ 

MedicalDevices/NewsEvents/ 

WorkshopsConferences/default.htm’’. 

Dated: August 27, 2010. 

David Dorsey, 

Acting Deputy Commissioner for Policy, 

Planning and Budget. 

[FR Doc. 2010–21801 Filed 8–31–10; 8:45 am] 

BILLING CODE 4160–01–S 


hsrobinson on DSK69SOYB1PROD with NOTICES